Madrigal Pharmaceuticals Quarterly Income Statement
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Madrigal Pharmaceuticals generated $364.3 million in revenue, up 71.2% from the same quarter a year earlier. Madrigal Pharmaceuticals reported a net loss of $57.9 million, compared with a loss of $42.3 million a year earlier. Operating margin was -15.5%.
Diluted earnings per share came in at -$1.99.
Summary generated from market data by MetaCap's automated system. Methodology
Madrigal Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 364.25M | 311.34M | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 |
| Revenue growth (YoY) | +71.17% | +126.84% | +210.77% | +362.03% | +1353.76% | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | 4.51M | — | — | — | 0 | — | — |
| Gross Profit | — | — | — | — | — | 132.74M | — | — | — | 0 | — | — |
| Operating Expenses | 420.56M | 404.06M | 380.69M | 401.24M | 260.00M | 216.56M | 170.32M | 178.48M | 177.18M | 152.04M | 117.18M | 98.53M |
| Research & Development | 91.18M | 108.69M | 116.27M | 174.00M | 54.08M | 44.17M | 25.65M | 68.74M | 71.09M | 71.24M | 70.64M | 70.95M |
| Selling, General & Admin | 289.38M | 268.52M | 239.98M | 209.12M | 196.86M | 167.88M | 141.22M | 107.58M | 105.45M | 80.80M | 46.54M | 27.58M |
| Operating Income | -56.31M | -92.72M | -59.61M | -113.97M | -47.20M | -79.31M | -67.00M | -116.30M | -162.54M | -152.04M | -117.18M | -98.53M |
| Interest Expense | 7.94M | 7.82M | 8.30M | 7.45M | 3.26M | 3.30M | 3.50M | 3.68M | 3.66M | 3.84M | 3.97M | 3.50M |
| Other Income (Expense) | -795.00K | -2.09M | -128.00K | -293.00K | -42.00K | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Net Income | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M | -106.96M | -151.97M | -147.54M | -112.19M | -98.74M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.99 | -3.25 | -2.03 | -4.01 | -1.50 | -2.61 | 2.09 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| EPS (Diluted) | -1.99 | -3.25 | -2.03 | -4.01 | -1.50 | -2.61 | 2.09 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| Shares Outstanding (Basic) | 29.15M | 29.03M | — | 28.51M | 28.23M | 28.09M | — | 21.75M | 21.40M | 20.00M | 19.76M | 18.48M |
| Shares Outstanding (Diluted) | 29.15M | 29.03M | — | 28.51M | 28.23M | 28.09M | — | 21.75M | 21.40M | 20.00M | 19.76M | 18.48M |
| EBITDA | -55.93M | -92.34M | -59.22M | -113.62M | -46.83M | -78.93M | -66.63M | -116.01M | -162.27M | -151.87M | -117.03M | -98.40M |
| Gross Margin | — | — | — | — | — | 96.71% | — | — | — | — | — | — |
| Operating Margin | -15.46% | -29.78% | -18.56% | -39.68% | -22.18% | -57.79% | -64.84% | -187.06% | -1110.38% | — | — | — |
| Net Margin | -15.91% | -30.32% | -18.24% | -39.75% | -19.87% | -53.36% | -57.51% | -172.04% | -1038.20% | — | — | — |
This table shows 12 quarterly periods of Madrigal Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MDGL's reporting calendar. What is a income statement?